US Stocks

argenx SE

argenx SE is a biotechnology company that develops therapies for autoimmune diseases in multiple countries, including the US and Japan. The company's lead product candidate is efgartigimod, which is currently in Phase III clinical trials for several conditions including myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. argenx SE is also developing several other product candidates for the treatment of cancer and autoimmune diseases.